Caroline Mosessian - 11 Nov 2022 Form 3 Insider Report for Vitro Biopharma, Inc.

Role
Chair of the Board, CRO, Director
Signature
/s/ Caroline Mosessian
Issuer symbol
N/A
Transactions as of
11 Nov 2022
Net transactions value
$0
Form type
3
Filing time
14 Nov 2022, 13:28:31 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding Employee Stock Option (Right to Buy) 11 Nov 2022 Common Stock 500,000 $0.5000 Direct F1
holding Employee Stock Option (Right to Buy) 11 Nov 2022 Common Stock 1,000,000 $0.5000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option became exercisable as to 100,000 shares on December 31, 2021, and will become exercisable as to (i) 100,000 shares on December 31, 2022, (ii) 100,000 shares on December 31, 2023, (iii) 100,000 shares on December 31, 2024, and (iv) 100,000 shares on December 31, 2025.
F2 The option became exercisable as to (i) 500,000 shares on October 1, 2021 and (ii) 125,000 shares on October 1, 2022, and will become exercisable as to (i) 125,000 shares on October 1, 2023 and (ii) 250,000 shares on October 1, 2024.